Vorinostat in Treating Patients With Kidney Cancer
Completed · Phase 2
Conditions studied: Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
In brief
This phase II trial is studying how well vorinostat works in treating patients with advanced kidney cancer. Drugs used in chemotherapy, such as vorinostat, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking blood flow to the tumor.
Key facts
- Study ID
- NCT00278395
- Run by
- National Cancer Institute (NCI)
- People needed
- 14
- Starts
- 2005-10-01
- Expected to finish
- 2010-02-01
- Last updated by the study team
- 2017-11-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically or cytologically confirmed diagnosis of advanced renal cell carcinoma that is either metastatic or inoperable
- Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
- Disease is recurrent or refractory to interleukin-2 (IL-2) or interferon-based therapy OR new diagnosis in previously untreated patients who are not appropriate candidates to receive IL-2 based treatment
- Patients who have failed up to 4 lines of prior immunotherapy or biological therapy allowed
- No known brain metastases or leptomeningeal disease
- Stable brain metastases or curatively resected brain metastases without neurologic dysfunction for ≥ 6 months allowed
- ECOG performance status 0-2 OR Karnofsky 70-100%
- Life expectancy ≥ 12 weeks
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Hemoglobin ≥ 9.0 g/dL
- Serum creatinine ≤ 1.5 times upper limit of normal (ULN) OR creatinine clearance > 50 mL/min
- Total bilirubin within normal limits
- AST/ALT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastasis is present)
- No history of active malignancy (other than renal cell carcinoma) within the past 3 years other than nonmelanomatous skin cancer, in situ breast cancer, or in situ cervical cancer
- No history of allergic reactions to compounds of similar chemical or biological composition to vorinostat (SAHA)
- No uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
- No psychiatric illness or social situation that would preclude study compliance
- No clinically significant hypercalcemia
- No significant traumatic injury within the past 21 days
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No gastrointestinal disease resulting in an inability to take oral medication
- No requirement for IV alimentation
Where it is running
- Cancer Therapy and Research Center at The UT Health Science Center at San Antonio — San Antonio, Texas, United States
- Institute for Drug Development — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.